



PRESS RELEASE

Final

SCIEX and QPS Holdings Enter Collaboration to Establish the BioBA Solution for Bioanalysis of Biologics

Agreement aims to advance the hybrid LBA-LCMS workflow for biologics quantification

Framingham, MA – April 5, 2016 - [SCIEX](#), a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX [BioBA Solution](#), the first end-to-end and most complete solution for bioanalysis of biologics.

Pharmaceutical and biopharmaceutical therapeutic portfolios have evolved from 10% large molecule therapies a little over a decade ago, to now nearly 50% of the entire pipeline. As organizations transition to biologics, new challenges arise for scientists characterizing and quantifying large molecules such as peptides, proteins, monoclonal antibodies, oligonucleotides, and antibody drug conjugates in complex biological matrices. SCIEX identified the challenges of quantifying protein biologics, and developed the BioBA solution to optimize robust, reproducible and sensitive quantification methods for proteins.

The comprehensive BioBA solution includes ready-to-use sample preparation kits, a fully automated liquid sample handler, a robust LC component with outstanding resolution, and a sensitive QTRAP[®] MS System with software for performing bioanalytical studies designed to support CFR 21 part 11 compliance. All this is supported by SCIEX's world-class expertise in biologics bioanalysis, while offering a rich repository of proven methods for many well-known biologics.

“Pharmaceutical and biopharmaceutical companies rely on CROs for productivity and robustness in bioanalytical analysis,” said Farzana Azam, Senior Director of Pharma/CRO Business at SCIEX. “The integrated BioBA solution enables scientists transitioning from traditional small molecule bioanalysis to biologics, to generate robust, reproducible and high-quality data. BioBA empowers scientists to turn the complexities of biologics bioanalysis into a simple process for both experts and non-experts, making the transition from small to large molecules easier than you think.”

“As a full CRO, we must meet the needs of the large pharmaceutical and biopharmaceutical industry in a productive manner with solutions that offer robustness and confidence,” said John Kolman, Executive Director and Head of Translational Medicine at QPS. “SCIEX’s BioBA solution is all about simplicity, standardization and efficiency, which offers QPS a running start towards achieving that right answer faster when it comes to large molecule bioanalysis.”

Learn more about the [SCIEX BioBA Solution](#)

About SCIEX

SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com.

SCIEX social: Twitter: [@SCIEXnews](#), [LinkedIn](#) and [Facebook](#).

For Research Use Only. Not for use in diagnostic procedures.

AB Sciex is operating as SCIEX.

© 2016 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.
RUO-MKT-12-3735-A

About QPS Holdings, LLC

Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) and life sciences products supplier supporting discovery, preclinical, and clinical drug development, providing quality services to pharmaceutical and biotechnology clients worldwide. QPS linearly integrated core competencies include: neuropharmacology, DMPK, liver research, toxicology, bioanalysis, translational medicine, and early and late phase clinical research program management. QPS regional laboratories and testing facilities are located at company headquarters in Newark, DE; Springfield, MO; Fargo, ND; Research Triangle Park, NC; Hollywood, FL; South Miami, FL, USA; Groningen, The Netherlands; Graz, Austria; Hyderabad, India; Barcelona, Spain; and Taipei, Taiwan.

For more information, visit <http://www.qps.com>, <http://hepaticbio.com>

###

Contact Information

Stacey Sicurella, Manager Global Public Relations and Brand, SCIEX
Stacey.sicurella@sciex.com
508-688-7958

Editorial follow-up

Patrick Farrell, Sniper Public Relations on Behalf of SCIEX
pfarrell@sniperpr.com
603-420-8828